Clinical Trial

Loncastuximab Tesirine in WM

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is being done to examine the safety and effectiveness of loncastuximab tesirine as a possible treatment for participants with Waldenström Macroglobulinemia (WM). The name of the study drug involved in this study is: * Loncastuximab tesirine
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2021-12-29; most recent amendment 2026-05-18.
Status change: Recruiting → Active, Not Recruiting 2026-05-18
Status change: Not Yet Recruiting → Recruiting 2022-03-01
Trial Details
NCT Number NCT05190705
Lead Sponsor Shayna Sarosiek, MD
Collaborators: ADC Therapeutics S.A.
Conditions Waldenstrom Macroglobulinemia
Enrollment 21 participants
Start Date 2022-02-17
Primary Completion 2026-05-01 (estimated)
Study Completion 2028-08-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-20